drugset / Trial / NCT03059888

Trial of Orencia in Patients With Myasthenia Gravis

NCT03059888

NaSingle-groupOpen-labelTreatment

Summary

This pilot research study is being done to see if the drug abatacept (Orencia ®) will be helpful in treating patients with myasthenia gravis (MG) who do not respond satisfactorily to other drugs that are used to suppress the immune system. Abatacept has been successful in treating experimental MG in laboratory animals, and this study is to determine its effectiveness in patients with MG.

Timeline

Start
2017-04-12
Primary completion
2019-07-15
Completion
2019-07-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Abatacept Other / unclassified 125 mg Subcutaneous

Indications